Sex, Hormones and Gamma-Aminobutyric Acid (GABA) in Stress Induced Anhedonia in Depression
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03031665|
Recruitment Status : Recruiting
First Posted : January 25, 2017
Last Update Posted : August 28, 2019
|Condition or disease|
|Major Depressive Disorder|
|Study Type :||Observational|
|Estimated Enrollment :||144 participants|
|Official Title:||Sex, Hormones and GABA in Stress Induced Anhedonia in Depression|
|Actual Study Start Date :||March 1, 2017|
|Estimated Primary Completion Date :||April 30, 2021|
|Estimated Study Completion Date :||April 30, 2021|
Subjects experiencing a current episode of Major Depressive Disorder.
Subjects who have a history of Major Depressive Disorder, but have not had a depressive episode for at least two months.
Subjects who have no history of clinical depression or other psychological disorder.
- Blood oxygen level-dependent (BOLD) activation in response to stress [ Time Frame: Baseline. ]Region-specific BOLD activation in response to stress in hypothalamus, amygdala, medial prefrontal cortex, orbitofrontal cortex, anterior cingulate cortex, and hippocampus
- Network-specific effective connectivity [ Time Frame: Baseline ]Region-specific resting state connectivity of two networks (1) hypothalamus and amygdala, with medial prefrontal cortex and orbitofrontal cortex; and (2) hypothalamus and amygdala, with hippocampus
- GABA concentration [ Time Frame: Baseline ]Region-specific GABA concentration measured in rostral anterior cingulate cortex and dorsolateral prefrontal cortex
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03031665
|Contact: Amelia Moser, BSemail@example.com|
|Contact: David J Crowley, ALMfirstname.lastname@example.org|
|United States, Massachusetts|
|Belmont, Massachusetts, United States, 02478|
|Contact: Nara Nascimento, BA 617-855-4420 email@example.com|
|Principal Investigator: Diego Pizzagalli, PhD|
|Principal Investigator:||Diego A Pizzagalli, Ph.D.||Mclean Hospital|